Taxotere: profile and news
Addition of Taxotere® to Neoadjuvant Chemotherapy Doesn’t ... Apr 17, 2006
...cancer who received preoperative chemotherapy with doxorubicin and cyclophosphamide, the addition of preoperative or postoperative Taxotere® (docetaxel) did ... - Cancer Consultants (press release),
Taxotere®, Platinol®, and Herceptin® for Locally Advanced HER2 ... Apr 24, 2006
Researchers from the University of Miami and the University of California at Los Angeles have reported that a regimen of Taxotere (docetaxel), Platinol ... - Cancer Consultants (press release),
Cell Genesys Cancer Drug Gets FDA Fast-Track Status May 10, 2006
The first trial will compare GVAX to Taxotere chemotherapy plus prednisone. ... Cancer treatment Taxotere is made by French drug maker Sanofi-Aventis. ... - Wall Street Journal,
Cell Genesys Receives Fast Track Status for GVAX(R) Immunotherapy ... May 10, 2006
1) is enrolling chemotherapy naïve, asymptomatic patients without cancer-related pain and will compare GVAX cancer immunotherapy to Taxotere chemotherapy plus ... - Yahoo! News (press release)
Cell Genesys up on FDA GVAX fast track May 10, 2006
...cancer treatment before. The trial will compare GVAX to Sanofi-Aventis SA's Taxotere chemotherapy plus the steroid prednisone. In the ... - BusinessWeek
FDA Grants Fast Track Designation For Cell Genesys' GVAX ... May 10, 2006
Each Phase 3 trial is expected to enroll 600 patients and is designed to demonstrate a survival benefit compared to Taxotere plus prednisone. ... - Trading Markets,
Sanofi-aventis First Quarter of 2006: Sales growth of 9.6% on a ... May 4, 2006
...million Q1 2006 Change on a net sales comparable basis Lovenox(R) 624 +16.4% Plavix(R) 580 +21.1% Stilnox(R)/Ambien(R)/Ambien CR(TM) 441 +11.9% Taxotere(R) 430 ... - PR Newswire (press release),
Enbrel® May Reduce Fatigue Among Patients Receiving Chemotherapy Apr 24, 2006
...addition of Enbrel improves the ability of patients to tolerate weekly treatment with high doses of the chemotherapy drug Taxotere® (docetaxel), researchers ... - Cancer Consultants (press release),
Herceptin® May Change the Natural History of Patients with HER2 ... May 1, 2006
...associated with an increase in cardiac complications, Herceptin has been combined with non-cardiotoxic agents such as Navelbine, Taxotere® (docetaxel), Taxol ... - Cancer Consultants (press release),
Receives US FDA Approval For Use In Advanced Stomach Cancer Apr 17, 2006
...recently announced that following a priority review of the supplemental new drug application (sNDA), the FDA has approved TAXOTERE® (docetaxel) Injection ... - Pharmaceutical Processing,
GPC Biotech Reports Financial Results for First Quarter of 2006 May 3, 2006
...respectively, raising euro 36.2 million -- New clinical trial opened with satraplatin: -- Phase 1 trial evaluating satraplatin plus Taxotere® (docetaxel) in ... - Yahoo! News (press release)
Sanofi-aventis First Quarter of 2006: Sales growth of 9.6% on a ... May 4, 2006
...increase of 9.6%. Taxotere® recorded another excellent quarterly performance, both in Europe and the "Other countries" region. In the ... - Yahoo! News (press release)
Spectrum Pharmaceuticals Reports First Quarter 2006 Financial ... May 8, 2006
Symposium that showed satraplatin had anti-tumor activity in patients who had hormone-refractory prostate cancer (HRPC), and had received Taxotere(R) (docetaxel ... - PR Newswire (press release),
YM BioSciences reports third quarter 2006 operational and ... May 12, 2006
Entered into a collaborative agreement with Sanofi-Aventis to investigate the effect of combining tesmilifene and Taxotere(R) (docetaxel) for the treatment ... - MSN Money
Dendreon Drives On May 10, 2006
The trial results look even better after comparing the mild side-effects of Provenge to the current standard of care, Taxotere, which brings with it all the ... - Motley Fool
Spectrum Pharmaceuticals Reports First Quarter 2006 Financial ... May 8, 2006
...that showed satraplatin had anti-tumor activity in patients who had hormone-refractory prostate cancer (HRPC), and had received Taxotere® (docetaxel), with a ... - Yahoo! News (press release)
NeoRx Initiates Clinical Trial of Picoplatin in Colorectal Cancer ... May 10, 2006
In the treatment of metastatic hormone refractory prostate cancer, treatment with docetaxel (Taxotere(R)) is the current standard of care. ... - PharmaLive.com (press release),
Cancer survivor finds home in chemotherapy clinic Apr 21, 2006
She thought of all the people with cancer and the chemicals with names like characters from Middle Earth — Cytoxin, Carboplatin, Taxotere — and told him it ... - Santa Cruz Sentinel,
UPDATE 1-Sanofi Q1 net rises 53.6 pct, beats forecasts May 4, 2006
Cancer drugs Taxotere and Eloxatin reported sales of 430 million and 429 million euros compared with 425 million and 430 million expected respectively. ... - Reuters
Sanofi-Aventis Earnings Rise On Vaccines-Business Strength May 5, 2006
Other growth drivers included cancer treatments Eloxatin and Taxotere, insulin drug Lantus, and multiple-sclerosis treatment Copaxone. ... - Wall Street Journal,
Abraxis BioScience Announces Co-Promotion Agreement with ... Apr 26, 2006
Oncology article was published on the Phase III pivotal trialwhich included an accompanying editorial that discussed ABRAXANEcompared to Taxotere(R). The J ... - Finanzen.net,
Cell Genesys Reports First Quarter 2006 Financial Results May 8, 2006
...other, but also compare favorably to the previously published median survival of 18.9 months for metastatic HRPC patients treated with Taxotere(R) (docetaxel ... - International News Service,
Sanofi-Aventis Q1 Profit Surges 54%, Boosted By Higher Vaccines ... May 5, 2006
...new rapid-acting insulin analog. In March, FDA approved Taxotere to use in advanced stomach cancer. In late March, sanofi-aventis ... - Trading Markets,
ADVENTRX ANNOUNCES CLOSING OF MERGER WITH SD PHARMACEUTICALS May 1, 2006
...to be non-allergenic which may obviate the need for immunosuppressant premedication and SDP-014 is a novel detergent-free docetaxel (Taxotere(R)) formulation ... - Small Times
Cell Genesys Reports First Quarter 2006 Financial Results May 8, 2006
...also compare favorably to the previously published median survival of 18.9 months for metastatic HRPC patients treated with Taxotere® (docetaxel) chemotherapy ... - Yahoo! News (press release)
Sequential Two-Drug Combinations Explored in Advanced NSCLC Apr 20, 2006
...of stage IIIB or stage IV non-small cell lung cancer (NSCLC) with Navelbine® (vinorelbine) and Platinol® (cisplatin), followed by Taxotere® (docetaxel) and ... - Cancer Consultants (press release),
AstraZeneca boosts cancer line-up with drugs swap Apr 27, 2006
...backing for Abraxane was likely to create competitive pressure on Sanofi-Aventis's (SASY.PA: Quote, Profile, Research) established anti-cancer drug Taxotere. ... - Reuters.uk,
AstraZeneca boosts cancer drug line-up Apr 27, 2006
Brothers analysts said AstraZeneca's backing for Abraxane was likely to create competitive pressure on Sanofi-Aventis's established anti-cancer drug Taxotere. ... - Reuters.uk,
PSA levels may measure treatment efficacy Apr 18, 2006
...found men with androgen-independent (hormone-refractory) metastatic prostate cancer who were treated with the chemotherapy drug Taxotere (docetaxel) Injection ... - Monsters and Critics.com,
First Quarter Reporting Season Slows Down - Upcoming Week In ... Apr 30, 2006
In March, Sanofi-Aventis said it's TAXOTERE Injection Concentrate in combination with cisplatin and 5-fluorouracil has been approved by the FDA for treating ... - Trading Markets,
Biotech Roundup: Pfizer, ImClone, Novacea Apr 21, 2006
Novacea showed interesting efficacy in a Phase III trial of Calcitrol (DN-101) in combination with Taxotere in men with prostate cancer. ... - Minyanville.com,
Prostate Cancer Research May Be Faster With PSA Endpoints Apr 20, 2006
...that men with androgen-independent (hormone-refractory) metastatic prostate cancer who were treated with the chemotherapy drug Taxotere® (docetaxel) Injection ... - Medical News Today (press release),
ADVENTRX Announces Closing of Merger With SD Pharmaceuticals Apr 28, 2006
...non-allergenic which may obviate the need for immunosuppressant premedication and SDP-014 is a novel detergent-free docetaxel (Taxotere®) formulation intended ... - Yahoo! News (press release)
PSA changes predict treatment success Apr 19, 2006
...that men with androgen-independent (hormone-refractory) metastatic prostate cancer who were treated with the chemotherapy drug Taxotere (docetaxel) Injection ... - myDNA.com,
Prostate cancer research may be faster with prostate-specific ... Apr 18, 2006
The study found that men with androgen-independent (hormone-refractory) metastatic prostate cancer who were treated with the chemotherapy drug Taxotere. ... - News-Medical.net,
